1. Lee SY. [Helicobacter pylori infection and the Kyoto classification of gastritis]. Korean J Helicobacter Up Gastrointest Res. 2019; 19:81–87.
Article
2. Kim BC, Song MA, Kwon SH. Endoscopic characteristics of rugal hyperplasia and related acid condition in Helicobacter pylori-infected stomach. Clin Endosc. 2020; Dec. 15. [Epub].
https://doi.org/10.5946/CE.2020.020.
Article
3. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, et al. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication. Biomed Res Int. 2014; 2014:481607.
4. Kim JH, Lee SY, Lee SP, et al. The histologic detection of Helicobacter pylori in seropositive subjects is affected by pathology and secretory ability of the stomach. Helicobacter. 2018; 23:e12480.
Article
5. Tu H, Sun L, Dong X, et al. Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scand J Gastroenterol. 2014; 49:259–266.
6. Baek SM, Kim N, Kwon YJ, et al. Role of serum pepsinogen II and Helicobacter pylori status in the detection of diffuse-type early gastric cancer in young individuals in South Korea. Gut Liver. 2020; 14:439–449.
Article
7. Cha JH, Jang JS. Clinical correlation between serum pepsinogen level and gastric atrophy in gastric neoplasm. Korean J Intern Med. 2020; 35:550–558.
Article
8. Ichinose M, Watanabe M, Kato J. Re: Development of diffuse carcinoma in the gastric corpus in patients with rugal hyperplastic gastritis. Int J Cancer. 2013; 133:2259.
Article
9. Iijima K, Koike T, Abe Y, Shimosegawa T. Cutoff serum pepsinogen values for predicting gastric acid secretion status. Tohoku J Exp Med. 2014; 232:293–300.
Article
10. Lee SY, Moon HW, Hur M, Yun YM. Validation of western Helicobacter pylori IgG antibody assays in Korean adults. J Med Microbiol. 2015; 64(Pt 5):513–518.
Article